Impetigo
Conditions
Keywords
Altargo, Bactroban, Fucidin, Fusidic acid, Mupirocin, topical, Retapamulin, United Kingdom
Brief summary
Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more months of age. This study is designed to examine retapamulin use in the pediatric population less than nine months of age. We will conduct a five-year assessment of prescriptions for retapamulin using the General Practice Research Database. For each year of reporting, the observed frequencies of prescriptions of retapamulin, with or without same-day co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year reporting period will include five years of distinct, non-overlapping, non-cumulative prescription use of first exposure to retapamulin, with or without same-day co-prescription of topical mupirocin or fusidic acid.
Interventions
DRUGRetapamulin
Prescription for retapamulin
Same day prescriptions for retapamulin and topical mupirocin
DRUGCo-prescription of retapamulin and topical fusidic acid
Same day prescription for retapamulin and fusidic acid.
Sponsors
GlaxoSmithKline
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The study population will consist of all registered research standard patients on GPRD, as evaluated annually for five years. For each year of observation, the denominator of persons will be patients registered for at least one month during the prior calendar year. Hence, the five-year reporting period for distinct, non-overlapping, non-cumulative prescription use and will categorize persons by date of birth (mm/dd/year).
Exclusion criteria
* Enrollment in GPRD of less than one month duration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prescription for retapamulin | First prescription in database for each calendar year between January 2007 and December 2011 |
Secondary
| Measure | Time frame |
|---|---|
| Co-prescription of retapamulin and topical mupirocin | First same-day prescriptions for both medicines in database for each calendar year between January 2007 and December 2011 |
| Co-prescription of retapamulin and topical fusidic acid | First same-day prescriptons for both medicines in database for each calendar year between January 2007 and December 2011 |
Outcome results
None listed